The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

May 22, 2026 updated by: Telix Pharmaceuticals (Innovations) Pty Limited

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment

The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The primary objective of the study is to compare radiographic progression-free survival (rPFS) in participants who receive 177Lu-TLX591 with SOC to rPFS in participants who receive SOC only.

This study consists of three Parts:

  • Part 1: Safety and Dosimetry Lead-in,
  • Part 2: Randomized Treatment Expansion, and
  • Part 3: Long-term Follow-up

The study will commence with a 30-patient safety and dosimetry lead-in (Part 1) and proceed to a randomization treatment expansion in approximately 490 patients (Part 2).

Patients in Part 2 will be randomized in a 2:1 ratio to receive either 177Lu-TLX591 + Standard of Care SoC (Group A), or SoC alone (Arm B).

SoC in this trial is either: ARPI (enzalutamide or abiraterone) or docetaxel.

All patients will be followed in long-term follow-up for at least 5 years from the first therapeutic dose, death, or loss to follow up (Part 3).

Only patients that meet PSMA-positivity criteria per Blinded Independent Central Review (BICR) will be eligible for this study.

Study Type

Interventional

Enrollment (Estimated)

520

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
      • Brisbane, Australia, 4101
        • Not yet recruiting
        • Mater Health Services Pty Ltd
        • Principal Investigator:
          • Niara Oliveira
        • Contact:
      • East Maitland, Australia, 2323
        • Recruiting
        • GenesisCare Maitland
        • Contact:
        • Principal Investigator:
          • Sangeetha Ramanujan
      • Heidelberg, Australia, 3084
      • Malvern, Australia, 3144
        • Recruiting
        • GensisCare Cabrini
        • Contact:
        • Principal Investigator:
          • Mario Guerrieri
      • North Adelaide, Australia, 5006
      • Saint Leonards, Australia, 2065
        • Recruiting
        • Royal North Shore Hospital
        • Principal Investigator:
          • Alexander Guminski
        • Contact:
      • Tugun, Australia, 4224
        • Recruiting
        • GenesisCare Tugun
        • Contact:
        • Principal Investigator:
          • Sagar Ramani
    • New South Wales
      • Sydney, New South Wales, Australia, 2747
      • Sydney, New South Wales, Australia, 2143
        • Recruiting
        • Westmead Hospital
        • Contact:
          • Study Coordinator
          • Phone Number: +61 2 8890 8383
        • Contact:
        • Principal Investigator:
          • Dr. Tania Moujaber
      • Wollongong, New South Wales, Australia, 2500
    • Victoria
      • Melbourne, Victoria, Australia, 3051
        • Recruiting
        • Australian Prostate Centre
        • Contact:
        • Principal Investigator:
          • Prof. Tony Costello
    • Western Australia
      • Perth, Western Australia, Australia, 6150
        • Recruiting
        • GenesisCare Murdoch
        • Contact:
        • Principal Investigator:
          • Dr. Aviral Singh
  • Canada
      • Burnaby, Canada
      • Toronto, Canada
        • Recruiting
        • Sunnybrook Research Institute
        • Contact:
        • Principal Investigator:
          • Urban Emmenegger
  • New Zealand
      • Christchurch, New Zealand, 8011
        • Recruiting
        • New Zealand Clinical Research - Christchurch
        • Contact:
        • Principal Investigator:
          • Anthony Rahman
    • Auckland
      • Grafton, Auckland, New Zealand, 92024
  • Turkey (Türkiye)
      • Ankara, Turkey (Türkiye)
        • Not yet recruiting
        • Ankara Bilkent City Hospital
        • Contact:
        • Contact:
        • Principal Investigator:
          • Elif Özdemir
      • Ankara, Turkey (Türkiye)
        • Recruiting
        • Hacettepe University Medical Faculty
        • Contact:
        • Contact:
        • Principal Investigator:
          • Murat Bozkurt
      • Ankara, Turkey (Türkiye)
        • Recruiting
        • Ankara University Cebeci Hospital
        • Principal Investigator:
          • Yuksel Urun
        • Contact:
        • Contact:
      • Istanbul, Turkey (Türkiye)
  • United Kingdom
  • United States
    • California
      • Orange, California, United States, 92868
        • Active, not recruiting
        • Chao Family Comprehensive Cancer Centre
    • Florida
      • Miami, Florida, United States, 33165
        • Active, not recruiting
        • Biogenix Molecular LLC
    • Maryland
      • Glen Burnie, Maryland, United States, 21061
        • Active, not recruiting
        • United Theranostics
    • Nebraska
      • Omaha, Nebraska, United States, 68130
        • Active, not recruiting
        • XCancer Omaha
    • New York
      • New York, New York, United States, 10032
        • Recruiting
        • Columbia University Herbert Irving Comphrensive Cancer Center
        • Contact:
        • Principal Investigator:
          • Mark Stein
    • Ohio
      • Cleveland, Ohio, United States, 44106
        • Active, not recruiting
        • University Hospital
    • Oregon
      • Portland, Oregon, United States, 97239
        • Active, not recruiting
        • OHSU Knight Cancer Center
    • Utah
      • Murray, Utah, United States, 84107
        • Active, not recruiting
        • Intermountain Health
      • Salt Lake City, Utah, United States, 84112
        • Active, not recruiting
        • Intermountain Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Be a male, at least 18 years old, with documented adenocarcinoma of the prostate defined by histological / pathological confirmation.
  • Be of ECOG Performance Status 0, 1, or 2 and have an estimated life expectancy of ≥6 months from Day 1.
  • Have metastatic disease (defined as ≥1 metastatic lesion present on baseline CT, MRI or bone scintigraphy).
  • Have castration-resistant PC (defined as disease progressing despite castration by orchiectomy or ongoing use of luteinizing hormone-releasing hormone [LHRH] analogues) and must have a castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L) at Screening
  • Must have received a minimum of 12 weeks of prior therapy on an ARPI (abiraterone, apalutamide, darolutamide, or enzalutamide), received in either the mCSPC, nmCRPC, or mCRPC treatment settings, with documented evidence of disease progression while receiving this ARPI. Progression must have occurred on the most recent ARPI. A prior ARPI may have been utilized, but no progression on the prior ARPI is allowed (e,g, ARPI was switched due to poor tolerability or due to adverse events). No washout period is required prior to enrollment into this trial. Participants may have received docetaxel in the mCSPC setting as per the CHAARTED or STAMPEDE treatment regimens (up to 6 cycles of docetaxel), provided the last dose of docetaxel was ≥ 6 months prior to screening and ≥ 4 cycles of docetaxel were administered.
  • Have a disease that is progressing at study entry, despite a castrate testosterone level (<50 ng/dL or <1.7 nmol/L), by the demonstration of at least one of the following:
  • Two consecutive rising PSA values assessed sequentially at least one week apart, with the final measurement required to be a minimum of 2.0 ng/mL for study entry. Only the last measurement must meet or exceed 2.0 ng/mL.
  • Progressive disease or new lesion(s) in the viscera or lymph nodes as per RECIST1.1 or in bone as per PCWG3. Any ambiguous results are to be confirmed by other imaging modalities (e.g., CT or MRI scan).
  • Have disease that is PSMA-positive, as demonstrated by a 68Ga-PSMA-11 PET/CT or PET/MRI scan and confirmed as eligible by the Sponsor's appointed BICR.

Imaging-based eligibility review will be performed in two stages:

  1. Presence of metastases for exclusion: Screening CT and MRI will be assessed to exclude participants with brain metastasis with long-axis>1cm
  2. PSMA PET eligibility: Screening 68Ga-PSMA-11 PET/CT or PET/MRI will be assessed along with CT, MRI, and bone scans utilizing tumor to liver ratio (TLR) for PSMA positivity-based exclusion. TLR is defined as the ratio of tumor lesion SUVmax to liver SUVmean derived from a 3 cm 3D spherical region of interest (ROI).

PSMA positivity is defined as : At least 1 lesion with PSMA TLR≥2.

PSMA exclusion critieria: The presence of any of the following will result in the patient being ineligible for this trial:

i) visceral metastatic lesions that are ≥1 cm that have a PSMA TLR< 1 ii) Lytic bone metastatic lesions with a soft tissue component of at least 1 cm with a TLF <1.

iii) At least one metastatic lymph node lesion with short axis ≥2.5 cm with a TLF<1.

  • Must have recovered to ≤ Grade 2 from all clinically significant toxicities related to prior therapies (i.e., surgery, local radiotherapy, ARPI, chemotherapy, etc.) with the exception of alopecia. Specific conditions may be discussed with the medical monitor as needed.
  • Have adequate organ function at Screening:

Bone marrow:

  • Platelets ≥150×109/L.
  • Absolute neutrophil count ≥1.5 x 109/L.
  • Hemoglobin >10g/dL (with no red blood cell transfusion in the previous 4 weeks).

Liver function:

  • Total bilirubin ≤ 1.5× the upper limit of normal (ULN). For participants with known Gilbert's Syndrome ≤3× ULN is permitted.
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤3× ULN.

Renal function:

  • Creatinine clearance ≥45 mL/min determined using the Cockcroft-Gault formula.
  • Must understand the study and agree to adhere to all protocol requirements.
  • Participants must comply with the radiation protection rules (including hospital admissions and isolation) that are used by the treating institution to protect their contacts and the public, especially if a female partner of the participant is or could be pregnant.
  • Must agree to practice adequate precautions to prevent pregnancy in a partner and to avoid potential problems associated with radiation exposure to the unborn child (Recommendations related to contraception and pregnancy testing in clinical trials Version 1.1 [Clinical Trial Coordination Group {CTCG, 2024}]).

Exclusion Criteria:

  • Is unable to understand or is unwilling to sign a written informed consent document or to follow investigational procedures in the opinion of the Investigator.
  • Has PC associated with pathological findings consistent with small cell or any histology other than adenocarcinoma of the prostate. If there are minor (<20%) elements of neuroendocrine histology, this is acceptable.

  • Participants with a history of other malignancies that could significantly impact life expectancy or interfere with disease assessment will be excluded. Exceptions apply to participants with:

    1. Prior malignancy that has been adequately treated and has remained disease-free for at least 3 years (maybe confirmed by a scan, etc.).
    2. Adequately treated non-melanoma skin cancer.
    3. Superficial (non-muscle invasive) bladder cancer that is controlled and stable.
  • Has received prior treatment with monoclonal antibody (mAb) J591 or HuJ591 or any other PSMA targeted therapy.
  • Have received chemotherapy in the mCRPC or non-metastatic prostate cancer (nmCRPC) settings (note: prior docetaxel use in the mCSPC setting with CHAATERED or STAMPEDE regimens is permitted if the last dose of therapy was ≥6 months prior to screening and ≥4 cycles of docetaxel were administered).
  • Has known allergies, hypersensitivity, or intolerance to the investigational drug or its excipients.
  • Has received prior systemic anti-cancer therapy (e.g., chemotherapy, immunotherapy, or biological therapy) and/or radiation therapy within 4 weeks of enrolment (excluding ARPI and/or LHRH analogues).

OR are receiving other concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, or investigational therapy.

  • Has received prior treatment with radioisotopes, including but not limited to: 89Strontium, 153Samarium, 186Rhenium, 188Rhenium, 223Radium, or hemi-body irradiation within 6 months prior to enrolment.
  • Has received other investigational therapy within 4 weeks of enrolment.
  • Has known brain metastases with long-axis ≥1cm, or liver metastases with long-axis ≥1cm, or lytic bone metastases with long-axis ≥1cm.
  • Has a history of seizure and/or stroke within the past 6 months.
  • Has clinical or radiologic findings indicative of impending spinal cord compression or experience symptomatic spinal cord compression.
  • Has evidence of a serious active or sub-clinical infection or angina pectoris (New York Heart Association [NYHA] Class III or IV), significantly prolonged QT interval or other serious illness(es) involving the cardiac, respiratory, central nervous system, renal, hepatic or hematological organ systems, that might impair the ability to complete this study or could interfere with determination of causality of any adverse effects experienced in this study, or which require treatment that could interact with study treatment, particularly with enzalutamide.
  • Has received treatment with any PARP inhibitors (i.e., Olaparib) or with any platinum based anti-neoplastic drugs.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 177Lu-TLX591 + Enzalutamide or Abiraterone or Docetaxel

Lutetium (177Lu) rosopatamab tetraxetan (177Lu-TLX591) 76 mCi (±10%) given approximately 14 days apart, plus SOC.

SOC is either:

Concurrent enzalutamide (starting dose 160 mg daily) + prednisone / prednisolone (5 mg twice a day) or equivalent.

or

Concurrent abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)

or

Sequential Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone (5mg twice a day) or equivalent for up to 10 cycles.
Drug: 177Lu-TLX591
Participants randomized to Group A will receive two 76 mCi (±10%) doses of 177Lu-TLX591 14 days apart
Other Names:
  • Lutetium (177Lu) rosopatamab tetraxetan
Drug: Enzalutamide
Enzalutamide (starting dose 160 mg daily)
Drug: Abiraterone
Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (up to 10 mg per day for the standard formulation)
Drug: Docetaxel
Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone 5mg twice a day (or equivalent) for up to 10 cycles
Active Comparator: Control Arm (Enzalutamide or Abiraterone or Docetaxel)

SOC is either:

Enzalutamide (starting dose 160 mg daily).

or

Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (up to 10 mg once daily for the standard formulation)

or

Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone 5mg twice a day (or equivalent) for up to 10 cycles
Drug: Enzalutamide
Enzalutamide (starting dose 160 mg daily)
Drug: Abiraterone
Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (up to 10 mg per day for the standard formulation)
Drug: Docetaxel
Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone 5mg twice a day (or equivalent) for up to 10 cycles

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Radiographic Progression-free Survival
Time Frame: 337days
time from randomization to disease progression confirmed by central independent radiology review according to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria (which incorporates Response Evaluation Criteria in Solid Tumors, RECIST 1.1, for soft tissue lesions), or death (whichever occurs first)
337days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Survival
Time Frame: 5 years
Defined as the time from randomization, until death from any cause.
5 years
Objective Response Rate (ORR)
Time Frame: 337days
Tumor response in terms of PCWG3 criteria (which incorporates RECIST 1.1 for soft tissue lesions).
337days
Time to a first symptomatic skeletal event (SSE)
Time Frame: 337days
Time to a first SSE, defined as the use of external beam radiation to relieve bone pain, or occurrence of a new symptomatic pathological fracture (vertebral or non-vertebral), or occurrence of spinal cord compression, or tumor-related orthopedic surgical intervention.
337days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Telix Pharmaceuticals (Innovations) Pty Limited

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 26, 2024

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2030

Study Registration Dates

First Submitted

July 12, 2024

First Submitted That Met QC Criteria

July 24, 2024

First Posted (Actual)

July 25, 2024

Study Record Updates

Last Update Posted (Actual)

May 27, 2026

Last Update Submitted That Met QC Criteria

May 22, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 177Lu-TLX591-203

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metastatic Castration-resistant Prostate Cancer

Clinical Trials on 177Lu-TLX591

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe